A forum for researchers, students and applicants in the field of cyclodextrin technology
Underdog Pharmaceuticals, Inc., a pharmaceutical company designing engineered cyclodextrins to address atherosclerosis and other serious diseases of aging, has completed
Researchers led by Professor Peter Horby at the University of Oxford, in England say they have the first evidence that
In a pandemic like Covid-19 the urgent need excludes the development of new drugs, “conventional drug in new use” becomes
Gilead has signed non-exclusive voluntary licensing agreements with further generic pharmaceutical manufacturers based in Egypt and India to further expand supply
The Health Sciences Authority (HSA), in consultation with its Medicines Advisory Committee and infectious diseases experts informed healthcare professionals on
Vaccines against COVID-19 will hopefully give broad parts of the human population a safe level of immunity and are considered
The gender gap in coronavirus survival became apparent early in the pandemic. Reports from China indicated men were dying at
Bloombergs Businessweek published the story on how Gilead scineces prepared for the recently obtained emergency approval of the antiviral drug
Takeda Pharmaceutical Company Limited announced the results of the Phase 2 Pevonedistat-2001 trial. The study evaluated a cyclodextrin-enabled (SBECD) pevonedistat plus
Yesterday, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Chief Executive Officer John Higgins issued a letter to Ligand’s Captisol® customers. The
